PETER F. IOCONA - ATTORNEY AT LAW
ORANGE COUNTY'S "BEST" DUI DEFENSE

CALL NOW: 949-305-0343 - FREE CONSULTATION - PAYMENT PLANS

ORANGE COUNTY DUI METHAMPHETAMINE DEFENSE


CONTACT US TODAY


ATTORNEY BIOGRAPHIES


 
CLIENT REVIEWS &
PEER-REVIEW RATINGS



FOLLOW OUR DUI BLOGS


GOOGLE BLOGGER

OC DUI Lawyer Blog


GOOGLE BUSINESS PAGES


PETER F. IOCONA
ATTORNEY AT LAW

22982 LA CADENA DR #239
LAGUNA HILLS, CA. 92653




THE SOCAL LAW NETWORK

23152 VERDUGO DR #201
LAGUNA HILLS, CA. 92653

 



SHARE AND FOLLOW US ON SOCIAL MEDIA:


  



ALAN CASTILLO AND PETER F.  IOCONA BOTH SELECTED AS ONE OF ORANGE COUNTY'S TOP-RATED DEFENSE ATTORNEYS

Top-Rated OC DUI Attorney


PETER F. IOCONA: RATED BY "SUPER LAWYERS" 2015-2016


Super Lawyer Rated - Peter F. Iocona


PETER F. IOCONA SELECTED AS ONE OF THE "TOP 100 TRIAL LAWYERS" BY THE NATIONAL TRIAL LAWYERS ASSOCIATION


Top 100 Trial Lawyers - Peter F. Iocona



PETER F. IOCONA SELECTED AS ONE OF THE TOP CRIMINAL DEFENSE ATTORNEYS


America's Top 100 Criminal Defense Attorneys - Peter Iocona


PETER F. IOCONA SELECTED AS ONE OF THE NATION'S TOP ONE PERCENT ATTORNEYS BY N.A.D.C. 


Peter F. Iocona - Top One Percent Rated Attorney


PETER F. IOCONA SELECTED AS A MEMBER OF THE NATIONAL ADVOCACY OF DUI DEFENSE


Nationally Ranked Superior DUI Attorney


FEATURED IN THE "TOP 100" MAGAZINE AS ONE OF THE NATION'S TOP 100 LAW FIRMS

Top 100 Magazine - Peter Iocona - SoCal Law Network

 "MEMBER" OF THE CALIFORNIA DUI LAWYERS ASSOCIATION


DUI Defense Lawyer - California DUI Lawyers Association


"MEMBER" OF THE NATIONAL COLLEGE FOR DUI DEFENSE


DUI Lawyer - National College for DUI Defense


"MEMBER" OF THE DUI DEFENSE LAWYERS ASSOCIATION (DUIDLA)


DUI Defense Lawyer - DUIDLA Member

  
ALAN CASTILLO SELECTED AS 
ONE OF THE "TOP 100 TRIAL LAWYERS" BY THE NATIONAL TRIAL LAWYERS ASSOCIATION



Top 100 Trial Lawyers - Alan Castillo


ALAN CASTILLO SELECTED AS 
ONE OF THE NATION'S TOP ONE PERCENT ATTORNEYS BY N.A.D.C. 


Alan Castillo - Top One Percent Rated Attorney



FORMER CONTRIBUTING EDITORS TO "CALIFORNIA DRUNK DRIVING LAW "
(2003-2016)


California Drunk Driving Law - Contributing Editors (2003-2016)



LAWYER LEGION COMMUNITY INVOLVEMENT AWARD 


Lawyer Legion - Top Attorney



"LEAD COUNSEL" RATED DEFENSE ATTORNEYS


Lead Counsel Rated Orange County DUI Attorneys



 LAWYER.COM VERIFIED DEFENSE ATTORNEYS





 BETTER BUSINESS BUREAU RATED "A+"


BBB Top Rating - Top-Rated DUI Attorneys



EVERY ATTORNEY IS RATED "10/10" OR "SUPERB" BY AVVO ATTORNEY RATING SERVICE


Peter F. Iocona - Top-Rated Orange County DUI Lawyer

PETER F. IOCONA RATED "SUPERB" "10/10" BY AVVO



Peter F. Iocona - Best Orange County DUI Lawyer

PETER F. IOCONA RECEIVED "CLIENT'S CHOICE AWARD" 
FROM AVVO RATING SERVICE


Peter F. Iocona - Top Orange County DUI Attorney

 PETER F. IOCONA AWARDED 
"TOP CONTRIBUTOR" BY AVVO





ALAN CASTILLO RATED "SUPERB" BY AVVO





 
ALAN CASTILLO RECEIVED "CLIENTS' CHOICE AWARD" 
FROM AVVO RATING SERVICE





 MARLO CORDERO RATED
"SUPERB" BY AVVO


CALL NOW FOR A FREE DUI CONSULTATION:


Click to call

ON-CALL 24 HOURS A DAY 7 DAYS A WEEK

SHARE AND FOLLOW US ON SOCIAL MEDIA:


  


  


ORANGE COUNTY DUI METHAMPHETAMINE DEFENSE

RATED BY SUPER LAWYERS, ORANGE COUNTY'S TOP-RATED DUI DEFENSE ATTORNEYS

Peter F. Iocona - Top 100 Trial LawyersPeter F. Iocona - Super Lawyers Rated Orange County DUI Lawyer  Peter F. Iocona - Top-Rated DUI Criminal Defense Attorney
 Peter F. Iocona - Top-Rated Orange County DUI Defense Attorney

DRIVING UNDER THE INFLUENCE OF METHAMPHETAMINE - DUI METHAMPHETAMINE


Methamphetamine is a white, beige, or light brown crystalline powder, or clear chunky crystals. There are two types of methamphetamine; D- and L-. The D- type is the one used illicitly, which is commonly referred to as “street methamphetamine”. The L- type methamphetamine is commonly found in non-prescription inhalers has a different effect. The L- type of methamphetamine is also commonly found in weight-loss medications as well; but can have similar effects to “street methamphetamine” in some cases.

Most street methamphetamine is produced in secret, underground laboratories and is commonly referred to as “speed,” “meth,” and “chalk.” Methamphetamine hydrochloride is clear chunky crystals resembling ice and it is commonly referred to as “ice,” “crystal,” “glass,” or “tina” depending on who you ask.

DUI Methamphetamine - Orange County


Methamphetamine is a common basis for a DUI charge for two reasons. First, an emerging population of regular users of illicit methamphetamine continue to expand because it is typically cheaper than cocaine and more easily found. Second, methamphetamine intensifies, stimulates, and accelerates brain functions that can reduce the ability to drive safely. Drivers who take methamphetamine can experience extreme agitation, paranoia, or even extreme aggression and can often respond to everyday traffic conditions with erratic maneuvers that cause them to get stopped for suspicion of DUI Methamphetamine.


ORANGE COUNTY DUI METHAMPHETAMINE DEFENSE ATTORNEYS


If you were stopped for Driving Under the Influence of Methamphetamine, or DUI Methamphetamine, you need to have your case handled by a DUI Defense Lawyer who understands the not only the chemical composition of the substance, but who also understands the signs and symptoms of impairment. If you have been charged with DUI Methamphetamine, contact Peter F. Iocona and the DUI Defense Attorneys of The SoCal Law Network for a free consultation and case evaluation.

DIRECTIONS TO PETER F. IOCONA - ATTORNEY AT LAW IN LAGUNA HILLS






















Orange County DUI Lawyer
22982 La Cadena Dr #239 Laguna Hills, CA 92653 US
Phone: 949-305-0343 Website: http://www.oc-duilawyer.com/DUI-Methamphetamine-Speed.html


NHTSA DRUGS AND HUMAN PERFORMANCE FACT SHEETS

Methamphetamine (And Amphetamine)

Methamphetamine hydrochloride is a white to light brown crystalline powder, or clear chunky crystals resembling ice. Methamphetamine base is a liquid.

Synonyms: Methamphetamine: chalk, chrissy, crank, crystal, glass, go, hydro, ice, meth, rock candy, speed, whiz; Desoxyn®; Amphetamine: dextroamphetamine; Dexedrine®, Adderall®, Benzedrine®, DextroStat®, Biphetamine®, Gradumet®.

Source: The majority of street methamphetamine is produced in clandestine laboratories (e.g. reduction of l-ephedrine or d-pseudoephedrine over red phosphorus with hydroiodic acid, or reduction with sodium or lithium in condensed liquid ammonia). Methamphetamine remains concentrated in western U. S. states and some rural areas elsewhere. d-Methamphetamine is a schedule II controlled substance (Desoxyn®) available in 5 mg white, 10 mg pink, and 15 mg yellow strength tablets. Amphetamine is also a Schedule II controlled substance and is usually supplied as the sulfate salt of the d-isomer (Dexedrine®), or as the racemic mixture (Benzedrine®), or a mixture of the two (Adderall®). Dexedrine® is available in 5, 10, and 15 mg strength, orange/black capsules, or 5 mg tablets. Adderall® is available in 5, 7.5, 10, 12.5, 20, and 30 mg strength, blue or orange tablets.

Drug Class: CNS stimulant, sympathomimetic, appetite suppressant.

Medical and Recreational Uses: Medicinally, methamphetamine is used in the treatment of narcolepsy, attention deficit disorder (ADD), and attention deficit hyperactivity disorder (ADHD). Typical doses are 10 mg/day or up to 40 mg daily, and a course of greater than six weeks is not recommended. Methamphetamine is infrequently used in the treatment of obesity, overeating disorders, and weight loss due to its abuse potential. Amphetamine is also used in ADD, narcolepsy, and weight control. Recreationally, methamphetamine is abused to increase alertness, relieve fatigue, control weight, treat mild depression, and for its intense euphoric effects.

Potency, Purity and Dose: Purity of methamphetamine is currently very high, at 60-90%, and is predominantly d-methamphetamine which has greater CNS potency than the l-isomer or the racemic mixture. Common abused doses are 100-1000 mg/day, and up to 5000 mg/day in chronic binge use. Therapeutic doses of Desoxyn® are 2.5-10 mg daily, with dosing not exceed 60 mg/day. To treat narcolepsy, 5-60 mg/day of amphetamine is ingested in divided doses; and in ADD and ADHD doses of 2.5-10 mg/day is administered, depending on age.

Route of Administration: Methamphetamine users often begin with intranasal or oral use and progress to intravenous use, and occasionally smoking. In contrast to cocaine, the hydrochloride salt of methamphetamine can itself be smoked. Methamphetamine is used sometimes with alcohol or marijuana, particularly during the withdrawal phase.

Pharmacodynamics: Methamphetamine increases synaptic levels of the neurotransmitters dopamine, serotonin (5-HT) and norepinephrine, and has a and b adrenergic agonist effects. Norepinephrine is responsible for methamphetamine’s alerting, anorectic, locomotor and sympathomimetic effects; dopamine stimulates locomotor effects, psychosis, and perception disturbances; and 5HT is responsible for delusions and psychosis. Methamphetamine’s effects are similar to cocaine but its onset is slower and the duration is longer. Racemic amphetamine and d-amphetamine have similar chemical properties and actions to methamphetamine but are less potent.

Pharmacokinetics: Following oral administration, peak methamphetamine concentrations are seen in 2.6-3.6 hours and the mean elimination half-life is 10.1 hours (range 6.4-15 hours). The amphetamine metabolite peaks at 12 hours. Following intravenous injection, the mean elimination half-life is slightly longer (12.2 hours). Methamphetamine is metabolized to amphetamine (active), p-OH-amphetamine and norephedrine (both inactive). Several other drugs are metabolized to amphetamine and methamphetamine and include benzphetamine, selegeline, and famprofazone.

Molecular Interactions / Receptor Chemistry: Methamphetamine is metabolized to amphetamine via cytochrome P450 2D6. Potential inhibitors of the 2D6 isoenzyme could decrease the rate of methamphetamine elimination if administered concurrently, while potential inducers could increase the rate of elimination.

Blood to Plasma Concentration Ratio: 0.65 (N=1).

Interpretation of Blood Concentrations: Blood concentrations can generally be used to distinguish therapeutic use from abuse. Concentrations of 0.02-0.05 mg/L are typical for therapeutic use, and up to 0.2 mg/L have been documented. Concentrations greater than this represent abuse. Concentrations do not disclose phase of use. Normal concentrations in recreational use are 0.01 to 2.5 mg/L (median 0.6 mg/L). Concentrations above this range will likely be associated with severe, possibly life threatening, toxicity. There is no evidence for improved performance in any task or test following use of doses greater than 40 mg (or concentrations greater than 0.2 mg/L).

Peak blood methamphetamine concentrations occur shortly after injection, a few minutes after smoking, and around 3 hours after oral dosing. Peak plasma amphetamine concentrations occur around 10 hours after methamphetamine use.

Interpretation of Urine Test Results: Positive results generally indicate use within 1-4 days but could be up to a week following heavy chronic use. Rate of excretion into the urine is heavily influenced by urinary pH. Between 30-54% of an oral dose is excreted in urine as unchanged methamphetamine and 10-23% as unchanged amphetamine. Following an intravenous dose, 45% is excreted as unchanged parent drug and 7% amphetamine.

Effects: Methamphetamine effects are less intense after oral ingestion than following smoked or intravenous use. Early phase – Psychological: Euphoria, excitation, exhilaration, rapid flight of ideas, increased libido, rapid speech, motor restlessness, hallucinations, delusions, psychosis, insomnia, reduced fatigue or drowsiness, increased alertness, heightened sense of well being, stereotypes behavior, feelings of increased physical strength, and poor impulse control. Early phase – Physiological: Increased heart rate, increased blood pressure, increased respiration rate, elevated temperature, palpitations, irregular heartbeat, dry mouth, abdominal cramps, appetite suppressed, twitching, pallor, dilated pupils, HGN at high doses, faster reaction time, increased strength, and more efficient glucose utilization. Late phase – Psychological: Dysphoria, residual stimulation, restlessness, agitation, nervousness, paranoia, violence, aggression, lack of coordination, pseudo-hallucinations, delusions, psychosis, and drug craving.

Late phase – Physiological: Fatigue, sleepiness with sudden starts, itching/picking/scratching, normal heart rate, and normal to small pupils which are reactive to light.

Binge use of methamphetamine can be broken down into the following phases: Rush – (5 minutes) intense euphoria, rapid flight of ideas, sexual stimulation, high energy, obsessive/compulsive activity, thought blending, dilated pupils; Shoulder –

(1 hour) less intense euphoria, hyperactivity, rapid flight of ideas, obsessive/compulsive activity, thought blending, dilated pupils; Binge use – (1-5 days) the drug is frequently readministered in an attempt to regain or maintain euphoria; Tweaking – (4-24 hours) dysphoria, scattered and disorganized thought, intense craving, paranoia, anxiety and irritability, hypervigilance, auditory and tactile hallucinations, delusions, and normal pupils; Crash – (1-3 days) intense fatigue, uncontrollable sleepiness and catnapping, continuing stimulation, drug craving; Normal – (2-7 days) apparent return to “normalcy” although drug craving may appear; Withdrawal – anergia, anhedonia, waves of intense craving, depression, hypersomnolence, exhaustion, extreme fatigue.

Side Effect Profile: Light sensitivity, irritability, insomnia, nervousness, headache, tremors, anxiety, suspiciousness, paranoia, aggressiveness, delusions, hallucinations, irrational behavior, and violence. In overdose, symptoms may include hyperthermia, tachycardia, severe hypertension, convulsions, chest pains, stroke, cardiovascular collapse, and possible death. Other common side effects following abuse of amphetamines include viral hepatitis, Sexually Transmitted Diseases (STDs), HIV, septicemia, abscesses, collapsed blood vessels, and malnutrition. Chronic abuse generally produces a psychosis that resembles schizophrenia and is characterized by paranoia, picking at the skin, preoccupation with one’s own thoughts, and auditory and visual hallucinations. Violent and erratic behavior is frequently seen among chronic abusers. Over time, methamphetamine appears to cause reduced levels of dopamine, which can result in symptoms like those of Parkinson’s disease.

Duration of Effects: Onset of effects is rapid following intravenous use and smoking, while effects onset more slowly following oral use. Overall effects typically last 4-8 hours; residual effects can last up to 12 hours.

Tolerance, Dependence and Withdrawal Effect: Methamphetamine has a high potential for abuse and dependence. Tolerance may develop and users may quickly become addicted and use it with increasing frequency and in increasing doses. Abrupt discontinuation of use can produce extreme fatigue, mental depression, apathy, long periods of sleep, irritability, and disorientation.

Drug Interactions: Phenobarbital, propoxyphene, phenytoin and MAOI’s slow the metabolism of amphetamines and increases their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings. Amphetamines may counteract sedative effects of antihistamines. Methamphetamine may restore ethanol induced impairment in simple repetitive tasks of short duration, however, there is no restoration of ethanol-induced deficits of balance and steadiness. In general, high doses of amphetamines are likely to increase the impairing effects of alcohol. Chlorpromazine and haloperidol block dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines. Amphetamine potentiates the analgesic effect of meperidine.

Performance Effects: Laboratory studies have been limited to much lower doses than those used by methamphetamine abusers. Doses of 10-30 mg methamphetamine have shown to improve reaction time, relief fatigue, improve cognitive function testing, increase subjective feelings of alertness, increase time estimation, and increase euphoria. However, subjects were willing to make more high-risk choices. The majority of laboratory tests were administered 1 hour post dose. Expected performance effects following higher doses may include agitation, inability to focus attention on divided attention tasks, inattention, restlessness, motor excitation, increased reaction time, and time distortion, depressed reflexes, poor balance and coordination, and inability to follow directions.

Effects on Driving: The drug manufacturer states that patients should be informed that methamphetamine and amphetamine may impair the ability to engage in potentially hazardous activities such as driving a motor vehicle. In epidemiology studies drive-off-the-road type accidents, high speed, failing to stop, diminished divided attention, inattentive driving, impatience, and high risk driving have been reported. Significant impairment of driving performance would also be expected during drug withdrawal. In a recent review of 101 driving under the influence cases, where methamphetamine was the only drug detected, blood concentrations ranged from <0.05-2.36 mg/L (mean 0.35 mg/L, median 0.23 mg/L). Driving and driver behaviors included speeding, lane travel, erratic driving, accidents, nervousness, rapid and non-stop speech, unintelligible speech, disorientation, agitation, staggering and awkward movements, irrational or violent behavior, and unconsciousness. Impairment was attributed to distraction, disorientation, motor excitation, hyperactive reflexes, general cognitive impairment, or withdrawal, fatigue and hypersomnolence.

DEC Category: CNS stimulant.

DEC Profile: Horizontal gaze nystagmus not present; vertical gaze nystagmus not present; lack of convergence not present; pupil size dilated; reaction to light slow; pulse rate elevated; blood pressure elevated; body temperature normal to down. Other characteristic indicators may include restlessness, body tremors, talkativeness, exaggerated reflexes, anxiety, and track marks or recent injection sites.

Panel’s Assessment of Driving Risks: At lower dose, amphetamines have few effects on cognitive functioning and may result in an enhancement of some psychomotor tasks, but risk-taking increases at higher doses and responses become inappropriate. Drug withdrawal could also lead to the impairment of psychomotor skills required for safe driving.

References and Recommended Reading:

Baselt RC. Drug effects on psychomotor performance. Biomedical Publications, Foster City, CA; pp 30-5, pp 244-6;2001.

Forney R. Stimulants, drugs & driving, NIDA research monograph 11, ed by Willette, RE 1977:73-6.

Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW, Hanson GR. Mechanisms for tolerance to methamphetamine effects. Neuropharmacol 1996;35(6):751-7.

Hurst PM. Amphetamines and driving. Alc Drugs Driv 1987;3(1):13-6.

Jerome L, Segal A. Benefit of long-term stimulus on driving in adults with ADHD. J Nerv Ment Dis 2001(1);189:63-4.

Logan BK. Amphetamines: an update on forensic issues. J Anal Toxicol 2001;25(5):400-4.

Logan BK. Methamphetamine and driving impairment. J Forensic Sci 1996;41(3):457-64.

Logan BK. Methamphetamine - Effects on Human Performance and Behavior. Forens Sci Rev 2002;14(1/2):133-51.

National Transportation Safety Board safety study: Fatigue, alcohol, other drugs, and medical factors in fatal-to-the-driver heavy truck crashes (vol I and II). Accession# PB90-917002, report# NTSB/SS-90/01/02, National Transportation Safety Board, Washington DC, 1990.

Perez-Reyes M, White WR, McDonald SA, Hicks RE, Jeffcoat AR, Hill JM, Cook CE. Clinical effects of daily methamphetamine administration. Clin Neuropharm 1991(4);14:352-8.

Physicians’ Desk Reference, Medical Economics Company, Montvale, NJ, 2002.

Smith DE, Fischer CM. An nalysis of 310 cases of acute high dose methamphetamine toxicity in Haight-Ashbury. Clin Toxicol 1970;3(1):117-24.

Website Builder